Mannatech vs Prenetics Global
MTEX and PRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MTEX and PRE compare
Prenetics Global grew revenue faster over the last twelve months (480% versus −5.0% for Mannatech).
Mannatech keeps more of each dollar of sales as profit, with a net margin of −6.9% compared with −40.8% at Prenetics Global.
Prenetics Global scores higher on the StockData Score (10 against 8 for Mannatech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MTEX | PRE |
|---|---|---|
| Size and price | ||
| Market cap | $16.5M | – |
| Share price | $8.57 | $17.64 |
| Change, 1 year | −11.4% | 48.4% |
| Change, 5 years | −77.5% | −88.1% |
| Beta (5Y) | 0.40 | 0.60 |
| Employees | 387 | 98 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× | – |
| EV/EBITDA | 3.6× | – |
| P/FCF | 10.4× | – |
| FCF yield | 9.7% | – |
| Growth | ||
| Revenue growth (TTM) | −5.0% | 480% (better) |
| Revenue growth, 5Y average | −6.5% | 7.2% (better) |
| Profitability | ||
| Gross margin | 76.1% (better) | 52.8% |
| Operating margin | 2.5% (better) | −48.1% |
| Net margin | −6.9% (better) | −40.8% |
| FCF margin | 1.5% (better) | −23.8% |
| Return on equity | −406% | −23.1% (better) |
| Return on invested capital | – | −29.0% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Net debt / EBITDA | −0.89 | – |
| Interest coverage | 5.9× | – |
| Current ratio | 1.15 | 2.97 (better) |
| Altman Z-score | 4.03 | – |
| Piotroski F-score | 2 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 7.9% | – |
| Held by insiders | – | 14.2% |
| Insider net buying, 12 months | $62.2K | $1000K (better) |
Go deeper
- MTEX stock overview
- MTEX income statement
- MTEX valuation and score
- PRE stock overview
- PRE income statement
- PRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.